New hope for HER2-Low breast cancer: experimental drug takes on market leader
NCT ID NCT07497386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a new drug, trastuzumab rezetecan, against an existing drug, trastuzumab deruxtecan, in 150 women with a common type of advanced breast cancer (HR-positive, HER2-low). The goal is to see which dose works best to slow cancer growth. Participants must have already tried hormone therapy without success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab rezetecan (an antibody-drug conjugate) compared to trastuzumab deruxtecan
What this could lead to
If successful, this could provide a new treatment option for people with HR-positive, HER2-low advanced breast cancer who have stopped responding to hormone therapy.
What could go wrong
This is a phase 2 trial with only 150 participants, so results are preliminary. The experimental drug may not be more effective or safer than the existing drug, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY RECURRENT BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact